Hyphens Pharma to develop and commercialise ByfavoR procedural sedation drug in Singapore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Hengrui Pharma and GSK Ink Agreement on 12 Innovative Drugs

In a recent move, Hengrui Pharma and GSK have...

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

Magnetic Particles Steer the Vesicles for Drug Delivery

Researchers have gone on to demonstrate that microscopic drug...

SGX-Catalist listed Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, has just announced that its subsidiary, Hyphens Pharma Pte. Ltd., has signed an exclusive sub-license and supply agreement with Hana Pharm Co., Ltd. to develop and commercialise Byfavo® 20mg (remimazolam besylate 20mg) in Singapore.

Byfavo® is an ultra-short-acting intravenous benzodiazepine anaesthetic drug that is used to induce and maintain sedation in adults undergoing short medical procedures such as colonoscopy. Clinical data has demonstrated that remimazolam has a rapid onset and offset of action combined with a favourable cardio-respiratory safety profile.

Mr TaeHong Choi, CEO and President of Hana Pharm, said: “We are delighted to begin new partnership with Hyphens, which has expertise in gastroenterology market. By solidifying the partnership between the two companies, we will move up approval and launching period as much as possible in Singapore, and take it as a bridgehead to enter the endoscopic procedural sedation market in other Southeast Asian countries.”

Mr Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: “Byfavo® 20mg is a welcome addition to boost our specialty pharma segment. We are happy to develop and commercialise Byfavo® 20mg in Singapore as it strengthens our gastroenterology portfolio that consists of brands like Vivomixx®. Byfavo® is a novel agent that we can offer to gastroenterologists and colorectal surgeons who perform colonoscopies. Byfavo® works quickly after administration, with rapid recovery and less drowsiness and grogginess after a procedure. Its favourable safety profile helps to reduce the risk of complications and adverse events during and after a procedure.”

Latest stories

Related stories

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Hengrui Pharma and GSK Ink Agreement on 12 Innovative Drugs

In a recent move, Hengrui Pharma and GSK have...

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

Magnetic Particles Steer the Vesicles for Drug Delivery

Researchers have gone on to demonstrate that microscopic drug...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back